This chart is a general guideline based on the FDA-approved labeling for Ozempic (semaglutide) as of 2024.
| | Dose | Pen Color | Action | | :--- | :--- | :--- | :--- | | Weeks 1–4 | 0.25 mg | Red pen | Starting dose (no blood sugar control yet) | | Weeks 5–8 | 0.5 mg | Red pen | Therapeutic dose begins | | Weeks 9–12 | 1.0 mg | Blue pen | Significant A1C reduction | | Week 13+ | 2.0 mg (Max) | Gold pen | Maximum studied dose | ozempic dose increase chart